Invest now
Neuland Laboratories share price
Balanced risk
You have to be logged in to add this to Watchlist.- ₹21,698.65(-0.88%)October 7, 2026 15:29:15 PM IST
- NSE
- BSE
- Vol : 65.41 K (NSE + BSE)Last 20 day avg : 56.09 K
Neuland Laboratories is trading -0.88% lower at Rs 21,698.65 as compared to its last closing price. Neuland Laboratories has been trading in the price range of 22,149.90 & 21,583.95. Neuland Laboratories has given 44.35% in this year & 2.17% in the last 5 days. Neuland Laboratories has TTM P/E ratio 47.89 as compared to the sector P/E of 33.65.There are 4 analysts who have initiated coverage on Neuland Laboratories. There are 2 analysts who have given it a strong buy rating & 2 analysts have given it a buy rating. 0.00 analysts have given the stock a sell rating.The company posted a net profit of 147.67 Crores in its last quarter.Listed peers of Neuland Laboratories include Aurobindo Pharma (-0.30%), Pfizer (-1.24%), Unichem Laboratories (-0.23%).The Mutual Fund holding in Neuland Laboratories was at 12.66% in 30 Jun 2026. The MF holding has increased from the last quarter. The FII holding in Neuland Laboratories was at 21.08% in 30 Jun 2026. The FII holding has increased from the last quarter.
- Overview
- Financials
- Forecast
- Technical Analysis
- Peers
- Shareholding
- About the company
- FAQ
Overview
- 1 D
- 5 D
- 1 M
- 3 M
- 6 M
- 1 Y
- 5 Y
- MAX
Loading...
Key Metrics
Updated on 07 Oct 2026, 10:27 PM IST
- BetaHigh volatility1.33Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
- Debt To EquityHigher than industry0.16The debt-to-equity ratio, indicating a company's financial leverage.
- Dividend YieldLower than industry0.16Annual dividends as a percentage of the stock price.
- P/BHigher than historical values14.99The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
- P/ELower than historical values56.46Price-to-earnings ratio based on trailing 12-month earnings
- PEG RatioIndicates Fair Valuation1.85The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
Price range
Day Range
|
| ||||
52 week range
|
| ||||
Neuland Laboratories News
Neuland Laboratories Peers
Return Comparison
Peers Comparison
Names | Price | %Change | Market Cap | P/E | P/B | Dividend Yield | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Aurobindo Pharma | 1,685.00 | -0.30 | 96,951.17 | 25.09 | 2.35 | 0.26 | 2.89 |
| Pfizer | 3,810.00 | -1.24 | 17,425.78 | 27.53 | 4.97 | 1.64 | 0.86 |
| Unichem Laboratories | 545.75 | -0.23 | 3,809.21 | 54.27 | 1.53 | - | 2.40 |
| Jagsonpal Pharmaceuticals | 234.75 | 0.21 | 1,544.94 | 34.27 | 5.43 | 1.12 | 2.39 |
| Themis Medicare | 117.55 | 2.89 | 1,039.72 | 632.19 | 2.54 | 0.45 | 5.48 |
Mutual Fund Ownership
View allNeuland Laboratories Corporate Actions
View all- Board Meetings
- AGM
- Dividends
- Bonus
- Split
- Rights
| Meeting Date | Purpose |
|---|---|
| 2026-08-05 | Quarterly Results |
| 2026-05-12 | Audited Results & Final Dividend |
| 2026-02-09 | Quarterly Results |
| 2025-11-07 | Quarterly Results |
| 2025-07-31 | Quarterly Results |
About the company Neuland Laboratories
- IndustryMajor Drugs
- ISININE794A01010
- BSE Code524558
- NSE CodeNEULANDLAB
Neuland Laboratories Ltd. is a global provider of active pharmaceutical ingredients (APIs) contract development and manufacturing organization (CDMO) services. It is focused on manufacture and sale of active pharmaceutical ingredients and allied services. It supports biotechnology and pharmaceutical companies in the design, development and manufacturing of complex APIs. It has two business verticals: generic drug substances (GDS) and custom manufacturing solutions (CMS). It develops and manufactures non-exclusive APIs both Prime APIs comprising large volume, mature molecules, and specialty APIs comprising lower volume, complex molecules with less competition. It develops small molecules and peptides for clinical trials and beyond. It provides an end-to-end continuum of customized services from early-stage drug development (Pre-IND) through to commercial manufacturing of complex APIs, including process development, process optimization, analytical testing, and regulatory support.
Neuland Laboratories Share Price FAQs
Neuland Laboratories is trading at 21698.65 as on Wed Oct 07 2026 09:59:15. This is -0.88% lower as compared to its previous closing price of 21891.65.
The market capitalization of Neuland Laboratories is 27732.01 Cr as on Wed Oct 07 2026 09:59:15.
The average broker rating on Neuland Laboratories is Strong Buy. The breakup of analyst rating is given below -
- 2 analysts have given a strong buy rating
- 2 analysts have given a buy rating
- 0.00 analysts have given a hold rating
- 0.00 analysts have given a sell rating
- 0.00 analysts have given a strong sell rating
The 52 wk high for Neuland Laboratories is 24235.05 whereas the 52 wk low is 11500.00
Neuland Laboratories can be analyzed on the following key metrics -
- TTM P/E: 47.89
- Sector P/E: 33.65
- Dividend Yield: 0.16%
- D/E ratio: -
Neuland Laboratories reported a net profit of 364.00 Cr in 2026.
The Mutual Fund Shareholding was 12.66% at the end of 30 Jun 2026.
Quick Links
EQUITY QUICK LINKS
Neuland Laboratories QUICK LINKS
FROM MARKETS
RELATED LINKS
✕
Wait for it…
Oops! Looks like you have exceeded the limit to bookmark the image. Remove some to bookmark this image.